ClinicalTrials.gg
RecruitingNCT05187338Updated Jun 25, 2024

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

A Phase 1/2 interventional study of ipilimumab +pembrolizumab +durvalumab in Lung Cancer, Liver Cancer and Colorectal Cancer, sponsored by Second Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by Second Affiliated Hospital of Guangzhou Medical University · Phase 1/2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing ipilimumab in Lung Neoplasms — 5 open to participants now, 7 under way, 1 of them phase 3. Ipilimumab · Lung Neoplasms.

Planned enrollment
9th of 20
100 · median 90
Started
2021
with 2 others
Phase 1/2
2 of 20
1 open now
Registered
17th of 20
by date
Lead sponsor
4 of 20
Second Affiliated Hospital of Guangzhou Medical University

Among the 20 studies testing ipilimumab in Lung Neoplasms, this one is the 9th largest by planned enrollment, is one of 3 that started in 2021, is one of 2 in phase 1/2, and was the 17th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

5 of the 20 studies testing ipilimumab in Lung Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ipilimumab

Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing ipilimumab in Lung Neoplasms, or all of them as a file.
02

Study summary

This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or intra-tumor (IT).

Read the detailed description

Malignant solid tumors including lung and liver cancers are the most common malignancy worldwide, and their mortality rates are very high. China has a huge population base with about 4,000,000 new cancer cases each year. More than 60% of the solid tumors in China are diagnosed at mid-to-late stage and have lost the chance of surgery. Recently a lot of therapeutic strategies have been developed and applied to clinic including targeted therapy and immunotherapy, but the overall therapeutic efficiency is still low. It is very difficult to treat patients with recurrent/refractory/metastatic advanced solid cancers and more alternative therapies are urgently needed.

Antibodies against CTLA4, PD1 and PDL1 are representative drugs for the check-points inhibitory agents, and their clinical indications have been approved in various types of tumors, including advanced melanoma, non-small cell lung cancer, renal cell carcinoma, and classical Hodgkin's lymphoma and late recurrent head and neck squamous cell carcinoma patients, et al. Those drugs are regularly systemically administrated by vein infusion, however, local delivery of those drugs via interventional radiology technique including trans-artery or intra-tumor injection may increase the local drug concentration of the tumor, improve the efficacy, and reduce systemic adverse reactions. CTLA4 antibody ipilimumab has been widely effectively using to combine with PD1 or PDL1 antibody and this study is to combine ipilimumab, PD1 antibody and PDL1 antibody, so called triplex checkpoint inhibitors combination therapy, for advanced solid tumors. To the investigator's knowledge, no studies have been developed on the safety, efficacy and survival benefit of the triplex checkpoint inhibitors combination therapy for cancer patients. This phase I-II clinical trial is designed to assess the safety and survival benefit of ipilimumab, pembrolizumab and durvalumab combination on patients with advanced solid cancers, including PFS, ORR, DCR, and median survival time.

03

Conditions studied

  • Lung Cancer
  • Liver Cancer
  • Colorectal Cancer
  • Pancreas Cancer
  • Ovary Cancer
  • Head and Neck Cancer
  • Breast Cancer
  • Gastric Cancer
  • Cervical Cancer
  • Esophageal Cancer
  • Sarcoma

Keywords

  • Solid tumor
  • CTLA4 antibody
  • PD1 antibody
  • PDL1 antibody
  • Interventional Radiology
  • Trans-artery infusion
  • Intra-tumor injection
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cytohistological confirmation is required for diagnosis of cancer.
  2. Signed before recruiting.
  3. Age above 18 years with estimated survival over 3 months.
  4. class A or B/Child score > 7; score \< 2
  5. Tolerable coagulation function or reversible coagulation disorders
  6. Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9/L; ≥90g/L; ≥50×10E9/L; \< 2.3 or PT \< 6 seconds above control;Cr ≤ 145.5 umul/L;Albumin > 28 g/L;Total \< 51 μmol/L
  7. At least one tumor lesion meeting criteria as determined by v1.1.
  8. .
  9. Willing and able to comply with scheduled visits, treatment plan and laboratory tests.

Exclusion criteria

Exclusion Criteria:

  1. Patients participated in clinical trials of equipment or drugs (signed ) within 4 weeks;
  2. Patients accompany by ascites, hepatic encephalopathy and esophageal and gastric varices bleeding;
  3. Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders;
  4. Patients accompanied with other tumors or past medical history of ;
  5. Pregnant or lactating patients, all patients participating in this trial must adopt appropriate measures during treatment;
  6. Patients have poor compliance.

    Any for hepatic arterial infusion procedure:

    A.Impaired clotting test ( count \< 60000/mm3, prothrombin activity \< 50%).

    B.Renal failure / insufficiency requiring hemo-or peritoneal dialysis. C.Known severe atheromatosis. D.Known uncontrolled blood hypertension (> 160/100 mm/Hg).

  7. Allergic to contrast agent;
  8. Any agents which could affect the absorption or pharmacokinetics of the study drugs
  9. Other conditions that investigator decides not suitable for the trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    3 drugs

    Three antibodies combination against PD1, PDL1, and CTLA4.

    Drug: ipilimumab +pembrolizumab +durvalumab

Interventions

  • Drugipilimumab +pembrolizumab +durvalumab

    Drug pages: IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DurvalumabStudies of DurvalumabDurvalumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This study has 3 subgroups: 1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks. 2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks. 3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Safety of 3 drugs combination treatment

    Safety will be assessed by recording all types of advise effects upon and after the treatment.

    Time frame: 5 years

  2. Progression-free survival

    Progression-free survival (PFS) will be defined as the elapsed time from the first date of study treatment until documented disease progression (as per RECIST 1.1) or death from any cause, whichever is earlier. For patients who remain alive without progression, follow-up time will be censored at the date of last disease assessment.

    Time frame: 5 years

  3. Disease control rate

    Disease control rate will be defined as objective response rate + steady disease rate.

    Time frame: 5 years

  4. Duration of remission (DOR)

    DOR will be defined as the duration of the cancer remission.

    Time frame: 5 years

Secondary outcomes

  1. Overall survival

    Overall survival (OS) will be defined as the elapsed time from the enrollment to death from any cause. For surviving patients, follow-up will be censored at the date of last contact (or last date known to be alive). Follow-up for OS will occur every 12 weeks (±1 month) until death or withdrawal of consent from the study.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510260, China
    Recruiting
    • Zhenfeng Zhang, MD, PHD · Contact
    • Bingjia He, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Oct 2029, 95 months after the start.

Of 78 non-industry phase 1/2 interventional studies under Lung Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 159. This study's planned 95 months is above that.

Counting every sponsor, half of 157 studies reached it within 54 months; a quarter within 39 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2021
First posted
Jan 11, 2022
StartActual
Nov 1, 2021
Primary completionEst.
Oct 30, 2029
CompletionEst.
Oct 30, 2035
Last update
Jun 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05187338
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University
Responsible party
Sponsor
First posted
Jan 11, 2022
Start date
Nov 1, 2021
Primary completion
Oct 30, 2029 (estimated)
Completion
Oct 30, 2035 (estimated)
Last update
Jun 25, 2024

Study contacts

Zhenfeng Zhang, MD, PHD
Contact
zhangzhf@gzhmu.edu.cn
+862039195966
Bingjia He, MD
Contact
464677938@qq.com
+862039195965
Zhenfeng Zhang, MD, PHD
principal investigator · Second Affiliated Hospital of Guangzhou Medical University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab · Pembrolizumab · Durvalumab

Start the discussion